People · Operator
Named in public records as an officer, director or promoter · active 2022–2023 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| RS BioTherapeutics Inc. | — | Pharmaceuticals | Seed | $1.9M | $7.7M | 2022 |
Michael Dean Guzman at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Michael Dean Guzman on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Curtis Rhine | 1 | 1 |
| H. Dean Hart | 1 | 1 |
| David Dean Freas | 1 | 1 |
| Justin Dean Molignoni | 1 | 1 |
| Curtis Dean Rhine | 1 | 1 |
| Dustin Dean Freas | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.